In patients with advanced ovarian cancer or other AXL-expressing tumors, engineered CARs that target AXL are introduced into NK cells isolated from the patients’ peripheral blood.161 Some CAR-NK are further genetically modified to produce and release IL7/CCL19 and/or scFvs against PD-1/CTLA4/Lag3, while others are combined with cannabidiol or nicotinamide adenine dinucleotide to enhance their cytotoxic potential (NCT05410717). This evidence concerns the gene AXL and ovarian cancer.